What happened
ImmuneOncia Therapeutics reported separate results for FY2025: revenue of US$75.6K (−83% year on year), an operating loss of US$19.2M and a net loss of US$18.8M.
Korean rules require this filing when revenue or profit moves 30% or more from the prior year (15% for large companies). The figures are the company's own and may not be audited yet.
| Revenue | US$75.6K |
|---|---|
| Revenue vs a year earlier | −83% |
| Operating profit | −US$19.2M |
| Net income | −US$18.8M |
| Period | FY2025 (separate) |
| Filed | 2026-02-06, Change of 30% or more in revenue or profit/loss structure (15% for large companies) |
| Source | DART rcept 20260206902374 → open original filing |
Source: DART. Information only, not investment advice.